Literature DB >> 6180095

Phase I-II trials of poly(ICLC) in malignant brain tumor patients.

O Nakamura, N Shitara, M Matsutani, K Takakura, H Machida.   

Abstract

Poly(ICLC) preparation, containing poly-L-lysine and poly(I) . poly(C) at a weight ratio of 1:2, was given intravenously at a dose of 0.05 to 0.2 mg/kg to 7 patients with malignant brain tumor. Poly(ICLC) induced significant serum interferon (more than 100 reference units/ml) in all patients. The highest interferon titer induced was 875 reference units/ml. Severe side effect was not observed except fever. Hypotension, leukopenia and elevation of liver enzyme levels were observed as side effects in a few cases.

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 6180095     DOI： 10.1089/jir.1982.2.1

Source DB:  PubMed          Journal:  J Interferon Res        ISSN： 0197-8357


  5 in total

Review 1.  Toll-like receptor agonists: are they good adjuvants?

Authors:  Sacha Gnjatic; Nikhil B Sawhney; Nina Bhardwaj
Journal:  Cancer J       Date:  2010 Jul-Aug       Impact factor: 3.360

2.  A North American brain tumor consortium phase II study of poly-ICLC for adult patients with recurrent anaplastic gliomas.

Authors:  Nicholas Butowski; Kathleen R Lamborn; Bee L Lee; Michael D Prados; Timothy Cloughesy; Lisa M DeAngelis; Lauren Abrey; Karen Fink; Frank Lieberman; Minesh Mehta; H Ian Robins; Larry Junck; Andres M Salazar; Susan M Chang
Journal:  J Neurooncol       Date:  2008-10-11       Impact factor: 4.130

3.  A phase II clinical trial of poly-ICLC with radiation for adult patients with newly diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05).

Authors:  Nicholas Butowski; Susan M Chang; Larry Junck; Lisa M DeAngelis; Lauren Abrey; Karen Fink; Tim Cloughesy; Kathleen R Lamborn; Andres M Salazar; Michael D Prados
Journal:  J Neurooncol       Date:  2008-09-17       Impact factor: 4.130

4.  Sensitivities of human glioma cell lines to interferons and double-stranded RNAs individually and in synergistic combinations.

Authors:  R S Dick; H R Hubbell
Journal:  J Neurooncol       Date:  1987       Impact factor: 4.130

5.  Trial Watch: Experimental Toll-like receptor agonists for cancer therapy.

Authors:  Lorenzo Galluzzi; Erika Vacchelli; Alexander Eggermont; Wolf Hervé Fridman; Jerome Galon; Catherine Sautès-Fridman; Eric Tartour; Laurence Zitvogel; Guido Kroemer
Journal:  Oncoimmunology       Date:  2012-08-01       Impact factor: 8.110
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.